LAURA PRIEST: Open Payments
NPI 1588308134 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,910 in 100 payments from 15 companies in 2025. Trend: 2023 $1,475 · 2024 $1,297 · 2025 $1,910
Food & beverage: $1,910
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $371 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $354 |
| ABBVIE INC. | 14 | $247 |
| Otsuka America Pharmaceutical, Inc. | 11 | $160 |
| Neurocrine BioSciences, Inc. | 9 | $150 |
| Alkermes, Inc. | 7 | $145 |
| Vanda Pharmaceuticals Inc. | 6 | $113 |
| Lundbeck LLC | 5 | $101 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Luye Pharma (USA) Ltd. | 2 | $52 |
Products named: CAPLYTA, AUSTEDO XR, VRAYLAR, REXULTI, INGREZZA, ARISTADA, UZEDY, FANAPT.
Industry payments across GA — which companies pay providers there.
